Development and implementation of a customised rapid syndromic diagnostic test for severe pneumonia

Vilas Navapurkar1*, Josefin Bartholdson Scott2*, Mailis Maes2, Thomas P Hellyer3,4, Ellen Higginson2, Sally Forrest2, Joana Pereira-Dias2, Surendra Parmar5, Emma Heasman-Hunt5, Petra Polgarova1, Joanne Brown1, Lissamma Titti1, William PW Smith6, Jonathan Scott3, Anthony Rostron3, Matthew Routledge5,7, David Sapsford8, M. Estée Török9,10, Ronan McMullan11, David A Enoch5, Vanessa Wong5,7, VAP-Rapid investigators, Martin D Curran5, Nicholas M Brown5, A John Simpson3,4, Jurgen Herre12, Gordon Dougan2, Andrew Conway Morris1,13

1John V Farman Intensive Care Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK
2Cambridge Institute of Therapeutic Immunology & Infectious Disease, University of Cambridge, Cambridge, CB2 0AW, UK
3Translational and Clinical Research Institute, University of Newcastle, Newcastle upon Tyne, NE2 4HH, UK
4Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, NE7 7DN, UK
5Clinical Microbiology and Public Health Laboratory, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK
6School of Clinical Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK
7Infectious Diseases, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK
8Pharmacy Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK
9Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK
10Microbiology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK
11Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, BT9 7BL, UK
12Respiratory Medicine, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK
13Division of Anaesthesia, Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK

* Equal contributors

Abstract

Background: The diagnosis of pneumonia has been hampered by a reliance on bacterial cultures which take several days to return a result, and are frequently negative. In critically ill patients this leads to the use of empiric, broad-spectrum antimicrobials and compromises good antimicrobial stewardship. The objective of this study was to...
establish the performance of a syndromic molecular diagnostic approach, using a custom TaqMan array card (TAC) covering 52 respiratory pathogens, and assess its impact on antimicrobial prescribing.

**Methods:** The TAC was validated against a retrospective multi-centre cohort of broncho-alveolar lavage samples. The TAC was assessed prospectively in patients undergoing investigation for suspected pneumonia, with a comparator cohort formed of patients investigated when the TAC laboratory team were unavailable. Co-primary outcomes were sensitivity compared to conventional microbiology and, for the prospective study, time to result. Metagenomic sequencing was performed to validate findings in prospective samples. Antibiotic free days (AFD) were compared between the study cohort and comparator group.

**Results:** 128 stored samples were tested, with sensitivity of 97% (95% confidence interval (CI) 88-100%). Prospectively, 95 patients were tested by TAC, with 71 forming the comparator group. TAC returned results 51 hours (interquartile range 41-69 hours) faster than culture and with sensitivity of 92% (95% CI 83-98%) compared to conventional microbiology. 94% of organisms identified by sequencing were detected by TAC. There was a significant difference in the distribution of AFDs with more AFDs in the TAC group (p=0.02). TAC group were more likely to experience antimicrobial de-escalation (odds ratio 2.9 (95%1.5-5.5)).

**Conclusions:** Implementation of a syndromic molecular diagnostic approach to pneumonia led to faster results, with high sensitivity and impact on antibiotic prescribing.

**Keywords**
Antimicrobial stewardship, Critical Care, Molecular pathology, Pneumonia
**Corresponding author:** Andrew Conway Morris (ac926@cam.ac.uk)

**Author roles:** Navapurkar V: Conceptualization, Funding Acquisition, Investigation, Project Administration, Resources, Supervision, Writing – Review & Editing; Bartholdson Scott J: Data Curation, Formal Analysis, Investigation, Resources, Writing – Original Draft Preparation, Writing – Review & Editing; Maes M: Investigation, Resources, Writing – Review & Editing; Pereira-Dias J: Investigation, Writing – Review & Editing; Higginson E: Investigation, Writing – Review & Editing; Forrest S: Investigation, Writing – Review & Editing; Parmar S: Investigation, Writing – Review & Editing; Heasman-Hunt E: Investigation, Writing – Review & Editing; Polgarova P: Data Curation, Investigation, Writing – Review & Editing; Brown J: Data Curation, Investigation, Writing – Review & Editing; Titti L: Data Curation, Investigation, Writing – Review & Editing; Smith WP: Data Curation, Writing – Review & Editing; Rostron A: Investigation, Resources, Writing – Review & Editing; Routledge M: Data Curation, Writing – Review & Editing; Sapsford D: Data Curation, Writing – Review & Editing; Török ME: Conceptualization, Data Curation, Investigation, Writing – Review & Editing; McMullan R: Investigation, Resources, Writing – Review & Editing; Enoch DA: Investigation, Writing – Review & Editing; Wong V: Data Curation, Formal Analysis, Investigation, Writing – Review & Editing; Curran MD: Conceptualization, Funding Acquisition, Investigation, Project Administration, Resources, Supervision, Writing – Review & Editing; Brown NM: Conceptualization, Investigation, Project Administration, Resources, Supervision, Writing – Review & Editing; Simpson AJ: Investigation, Resources, Writing – Review & Editing; Herre J: Conceptualization, Investigation, Resources, Writing – Review & Editing; Dougan G: Conceptualization, Funding Acquisition, Investigation, Project Administration, Resources, Supervision, Writing – Review & Editing; Conway Morris A: Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing

**Competing interests:** MDC is the inventor on a patent held by the Secretary of State for Health (UK Government) EP2788503, which covers some of the genetic sequences used in this study. VN is a founder, Director and shareholder in Cambridge Infection Diagnostics Ltd (CID Ltd) which is a commercial company aimed at developing molecular diagnostics in infection and antimicrobial and AMR stewardship. NMB, GD and ACM are members of the Scientific Advisory Board of Cambridge Infection Diagnostics Ltd (CID Ltd). All other authors declare no conflict of interest.

**Grant information:** Dr Conway Morris was supported by a Clinical Research Career Development Fellowship from the Wellcome Trust at the time of the work (205214) and is currently supported by an MRC Clinician Scientist Fellowship (MR/V006118/1). The study was funded by Addenbrooke’s Charitable Trust and the NIHR Cambridge Biomedical Resource Centre (Grant 18135 to Professor Dougan). Dr Török is supported by a Clinician Scientist Fellowship (funded by the Academy of Medical Sciences and the Health Foundation) and by the NIHR Biomedical Research Centre. The metagenomic sequencing was funded by the Wellcome Trust. VAPrapid was funded Health Innovation Challenge Fund (HICF-510-078;094949/Z/10/X), a parallel funding partnership between the UK Department of Health and Wellcome Trust. Professor Simpson is a National Institute for Health Research (NIHR) Senior Investigator. The views expressed in this publication are those of the authors and not necessarily those of the UK Department of Health or Wellcome Trust. The funders had no role in the analysis of data or decision to publish. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Copyright:** © 2022 Navapurkar V et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Navapurkar V, Bartholdson Scott J, Maes M et al. Development and implementation of a customised rapid syndromic diagnostic test for severe pneumonia [version 3; peer review: 2 approved] Wellcome Open Research 2022, 6:256 https://doi.org/10.12688/wellcomeopenres.17099.3

**First published:** 11 Oct 2021, 6:256 https://doi.org/10.12688/wellcomeopenres.17099.1
Amendments from Version 2
Following the comments from the second reviewer we have added a paragraph to the discussion concerning the changes in the pulmonary microbiome which can occur during mechanical ventilation in critical illness and how this can be challenging to distinguish from true infection, by both conventional and molecular microbial diagnostics.

Any further responses from the reviewers can be found at the end of the article.

Introduction
For many decades the diagnosis of infectious diseases has relied on a combination of clinical assessment and microbiological culture. However, cultures are frequently negative and can take several days to return a result. Optimising antimicrobial therapy can be challenging, especially in patients who are at risk of multidrug resistant organisms. In critically ill patients, this frequently results in the empiric use of broad-spectrum agents, with predictable consequences for antimicrobial resistance and other forms of antimicrobial-related harm such as drug toxicity and disruption of the microbiome. Conversely, failure to identify the causative organism can lead to inappropriate antimicrobial therapy, which is associated with poor outcomes.

Pneumonia amongst intubated and mechanically ventilated, critically ill patients can be especially difficult to diagnose. Most critically ill patients are systemically inflamed, clinical examination is unreliable and there are multiple causes of radiographic lung infiltrates, most of which are non-infectious.

The development of host-based biomarkers for infection, such as C-reactive protein, procalcitonin, and alveolar cytokine concentrations have been advanced as useful measures to help rationalise antimicrobial use. However, their utility in the diagnosis and antimicrobial stewardship of pneumonia has been challenged.

There is, therefore, a pressing need for rapid, sensitive, multipathogen-focused diagnostic tests for pneumonia. However, although intensive care physicians appreciate the potential advantages of such diagnostics, they are also wary of potential downsides, emphasising the need for evaluation of these tests in real-life clinical practice.

TaqMan array cards (TAC) enable the conduct of multiple simultaneous single-plex real-time polymerase chain reaction (RT-PCR), with this format allowing rapid and straightforward customisation. This customisation allows for a wider range of organisms than those found in existing commercially available tests, and rapid modification to address emerging threats. Although TACs have shown promising performance relative to conventional microbiology, our previous experience demonstrated that a TAC with restricted coverage of common respiratory pathogens had a limited impact on clinical decision making in critically ill patients. We therefore set out to develop and implement a multi-pathogen array that would have broad applicability for severe pneumonia.

Methods
Ethical and regulatory approvals and funding
The prospective study was approved by the Leeds East Research Ethics Committee (17/YH/0286), Cambridge University Hospitals NHS Foundation Trust was the sponsor, and registered with clinicaltrials.gov (NCT03996330). The assessment of routinely collected data from the comparator group received a consent waiver as data came from routinely collected clinical data and was conducted under a protocol approved by the institutional review board (A095506). The protocol has been deposited on Zenodo. VAPapid was approved by the England and Northern Ireland (13/LO/065) and Scotland (13/SS/0074) National Research Ethics Service committees and sponsored by Newcastle upon Tyne Hospitals NHS Foundation Trust.

Card development
The local microbial ecology was reviewed using previous conventional microbiological culture data from the hospital. This was supplemented by review of the literature concerning causative organisms reported in ventilator-associated and community-acquired pneumonia and the authors’ previous experience of molecular diagnostics in pneumonia. Species- or genus-specific primer/probe sequences were identified by reviewing the literature for well cited and fully validated real-time PCR assays with the presumption that, where possible, each organism should be covered by two sequences to minimise false positive results. In the absence of a published validated assay, one was designed in-house, normally targeting a housekeeping gene in the first instance (i.e. gyrB, rpoB, ssrA, dnaJ, recN) following the guidelines set out previously. Briefly, all assays were subjected to a comprehensive in silico analysis using BLAST analysis to ensure specificity of primers and probes and examined for possible cross-reactions with other high priority organisms. Potential for adverse probe/primer interactions and melting temperature (T_m) were assessed using OligoAnalyzer 3.1. If necessary, sequences were modified accordingly to remove any cross reactions and to ensure T_m of 55-60°C, to allow for uniform amplification.

The 52 organisms (23 bacteria, 2 mycobacteria, 6 atypical bacteria, 5 fungi and 16 viruses) covered by the card are shown in Figure 1. Sequences on the card have been deposited on Zenodo.

TAC procedure
Nucleic acid extraction from clinical samples was undertaken using the NUCLISENS easyMAG platform (cat number 280140, Biomerieux, Marcy L’Etoile, France), in accordance with the manufacturer’s instructions. Nucleic acids were extracted from 500 µL of input sample, with a dilution of MS2 bacteriophage added pre-extraction to act as an internal extraction and inhibition control.

Cards were run on the QuantStudio 7 Flex platform (cat number 4485701, ThermoFisher, Waltham, MA, USA), following a modified version of the method previously described. Briefly, 50 µL of each nucleic acid extract was mixed with...
**Figure 1.** A) TAC layout and targets, B) summary of organisms covered. * indicates organisms not routinely tested for by conventional microbiology in Clinical Microbiology and Public Health Laboratory, Public Health England, Cambridge. HCoV - human coronavirus.
50 µL of TaqMan Fast Virus 1-step mastermix (cat number 4444436, ThermoFisher) and 100 µL of RNase-free water, before 98 µL was added in 2 consecutive sample loading ports covering all 96 targets. Reverse transcriptase real-time PCR was undertaken according to the following amplification protocol: 50°C for five minutes, 95°C for 20 seconds, then 45 cycles of 95°C for one second followed by 60°C for 20 seconds. Detection of a clear exponential amplification curve with a cycle threshold (CT) value ≤38 for any single gene target was reported as a positive result for the relevant pathogen.

The study was undertaken prior to the coronavirus 2019 (COVID-19) pandemic.

Card validation

**Technical validation.** The card was initially validated against our large bank of DNA extracts from a diverse range of microorganisms, known positive/negative clinical specimens, and all available EQA panels from Quality Control for Molecular Diagnostics covering all targets except *C. burnetti*, *C. psittaci*, *C. pneumonia*, *M. pneumoniae* and *Elizabethkingia meningosep-tica*. For *C. burnetti*, *C. psittaci*, *C. pneumonia* and *M. pneumoniae* control DNA extracts were purchased (Vircell, Granada, Spain, Catalogue numbers MBC018, MBC013, MBC011 and MBC035 respectively). A panel of nine synthetic control plasmids containing all our target sequences (with 20 nucleotides each side of the primer target sites also included) were generated (*GenScript*, Leiden, NL) and used to quality check each batch of TAC plates and determine the limit of detection of each assay. As a demonstration of clinical utility, complete concordance was achieved against the five organisms from the Quality Control for Molecular Diagnostics 2018 Sepsis EQA Pilot Study (*Streptococcus pneumoniae, Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterococcus faecalis* and *Candida albicans* (Table 1)).

**Retrospective cohort validation.** A retrospective cohort validation was conducted using stored bronchoalveolar lavage (BAL) samples obtained during the 24 centre VArapid trial of a biomarker for the diagnosis of ventilator-associated pneumonia. VArapid centres used semi-quantitative microbiological culture as the reference standard but did not undertake routine testing for viruses or *Pneumocystis jirovecii*. The stored samples were analysed on the TAC using methods outlined above.

**Prospective evaluation.** The protocol for the prospective study, finalised prior to first recruitment, has been deposited on Zenodo. The prospective study was registered with clinicaltrials.gov (NCT03996330; June 24, 2019).

**Setting**

Patients were recruited from a 20-bedded teaching hospital Intensive Care Unit (ICU). The unit is a mixed general medical-surgical unit which supports transplant and haematology-oncology services.

**Recruitment**

Between February 2018 and August 2019, patients were eligible for inclusion if they were receiving invasive mechanical ventilation, and if the treating intensive care specialist (consultant) suspected pneumonia and was planning to perform diagnostic bronchoscopy. Exclusions were lack of a proxy decision maker to provide study assent, and lack of laboratory study

---

**Table 1. Performance of TaqMan array card in the Public Health England Quality Control for Molecular Diagnostics 2018 Sepsis EQA Pilot Study.** (TM: transport medium, ddl: D-alanine-D-alanine ligase).

| Sample content       | Matrix* | TaqMan array cards results (Ct Value)                                                                 |
|----------------------|---------|-------------------------------------------------------------------------------------------------------|
| Streptococcus pneumoniae | TM      | S pneumoniae #1 29.602 S pneumoniae #2 28.624 Streptococcus spp #1 29.060 Streptococcus spp #2 29.027 |
| Pseudomonas aeruginosa | TM      | P aeruginosa #1 28.806 P aeruginosa #1 28.350                                                          |
| Klebsiella pneumoniae   | TM      | K pneumoniae #1 25.650 K pneumoniae #2 25.106 Enterobacteriaceae 26.922                               |
| Enterococcus spp        | TM      | E faecalis ddl 26.641                                                                                |
| Streptococcus pneumoniae | Blood  | S pneumoniae #1 31.353 S pneumoniae #2 30.811 Streptococcus spp #1 31.735 Streptococcus spp #2 31.952   |
| Candida albicans        | Blood   | Candida albicans 34.313 Candida spp 33.124 Fungal 18S 30.839                                         |
| Pseudomonas aeruginosa  | Blood   | P aeruginosa #1 28.065 P aeruginosa #1 30.647                                                         |
| Klebsiella pneumoniae   | Blood   | K pneumoniae #1 26.770 K pneumoniae #2 25.213 Enterobacteriaceae 26.715                              |
| Enterococcus spp        | Blood   | E faecalis ddl 30.431                                                                                |
| Negative               | Blood   | PCR Negative                                                                                         |
team availability to perform the TaqMan array card assay (the laboratory study team were routinely unavailable from Friday 5pm to Monday 8am, and also sporadically unavailable due to leave). Patients were included consecutively when the study team was available. Written informed consent was obtained when patients had capacity at time of enrolment. For those lacking capacity, written proxy assent (nominated or personal consultee advice) was obtained prior to study inclusion, and retrospective consent was sought if capacity was regained whilst the patient remained in hospital. Patients were identified by the treating team and included prospectively and consecutively when the laboratory study team were available.

Patients who were not included in the study because of a lack of TAC laboratory team availability, and those from the month prior and month following the study, formed the comparator group.

Sampling procedure
Bronchoscopy for both TAC and comparator patients was conducted in accordance with the unit protocol. Briefly, the scope was wedged in a sub-segment of the area with maximal radiographic change, or where frank pus was seen emerging. In diffuse infiltrates a sub-segment of the right middle lobe or lingula was selected. Saline in 50ml aliquots up to a volume of 200ml was instilled and withdrawn after a dwell time of 10 seconds. Where samples were taken out of hours (Monday-Thursday 5pm-8am and Sunday 8am-Monday 8am), samples were stored at 4°C prior to processing within 24 hours, in accordance with existing laboratory procedures.

TAC testing
The samples for TAC were processed as set out above. The TAC was run by a dedicated laboratory team who did not undertake the conventional PCR or cultures, with blinding also assured by the results of the TAC being obtained before those from conventional microbiology.

Conventional microbiological testing
BAL samples were processed according to the UK Standards for Microbiology Investigations (SMI)24. Samples were inoculated onto a range of solid agars and incubated in both air and 5–10% CO₂, targeting conventional respiratory tract pathogens, Staphylococcus aureus, Enterobacteriales and Pseudomonads. Any organism with growth >10⁴ CFU/mL was identified to species level using matrix-assisted laser desorption isomisation time of flight (MALDI TOF) mass spectrometry (Bruker MALDI Biotyper Sirus (IVD) Bruker Ltd, Coventry, UK). A scanty mixed growth with no predominant organism was reported as ‘mixed respiratory tract flora’ and not characterised any further. Extended culture was performed for Legionella, Nocardia, anaerobes, fungi and Mycobacterium species. Growth at <10⁵ CFU/ml was reported as negative.

A single in-house multiplex PCR assay formed the basis of conventional testing for common respiratory viruses (adenovirus, enterovirus, human metapneumovirus, influenza A virus, influenza B virus, parainfluenza virus, rhinovirus, and respiratory syncytial virus). In-house monoplex PCR assays were used for the detection of Pneumocystis jirovecii. Aspergillus spp. were tested for by culture on Sabouraud Dextrose Agar with chloramphenicol (cat number PO0161A, Thermofisher), with or without testing for the presence of galactomannan antigen in serum (serum GM) and BAL (BAL GM) by Platelia™ Aspergillus enzyme immunoassay (cat number 62794, Bio-Rad Laboratories, Hercules, CA). As well as routine culture, Legionella pneumophila serotype 1 was tested for by the detection of antigen in urine, using the Alere BinaxNOW™ Legionella Urinary Antigen Card (cat number 852-000, Abbott Rapid Diagnostics, Stockport, UK) with positive tests confirmed in the national reference laboratory. Conventional laboratory methods were not routinely available to detect coronaviruses.

As an experimental assay, the results of the TAC were not included in the laboratory information system, blinding the assessors of the reference standard to the TAC results.

Return of results to clinical team
Following review by a consultant clinical scientist, results were returned to the ICU team. Clinical microbiology advice was available 24 hours/day, and patients underwent weekday daily combined ICU-Microbiology multi-disciplinary reviews in keeping with existing unit practice (weekend microbiology input was available on request). The study did not mandate any course of action by the treating clinical team. Conventional microbiology results were returned to clinicians via the electronic health record; however, in practice these were returned after the TAC results.

Outcome measures
The co-primary outcome measures were sensitivity, using conventional microbiology as the reference standard and time to result compared to conventional microbial culture. Time to result for microbial culture was taken as time from completion of lavage to first organism identification, or confirmation of negative growth if no organisms were detected.

Secondary outcome measures were sensitivity compared to metagenomic microbial sequencing, time to result compared to conventional PCR, days alive and free of antibiotics (antibiotic-free days, AFDS) in seven and 28 days following lavage and change in antibiotic therapy in the seven days following lavage. Qualitative assessment of whether TAC results impacted on antimicrobial change was assessed by clinical notes review by a member of the study team who was not involved in the decision-making process (VW).

Statistical analysis
The difference in median time to result for conventional culture and TAC was assessed by Wilcoxon’s matched-pairs test. Where conventional PCR failed, or where the lab did not test for the organism, the corresponding tests from the TAC were removed from calculation of diagnostic performance. Indeterminate cultures (‘mixed upper respiratory tract flora’) were
considered negative. A sensitivity analysis, coding failed conventional PCR and organisms not tested ‘negative’ was also undertaken. Comparisons of distribution of antibiotic free days between TAC and comparator groups was by Mann-Whitney U test, differences in proportions of escalation and de-escalation decisions were assessed by Chi² test. Analyses were conducted using Prism v9.1 (Graphpad Inc, La Jolla, CA).

Study size
A planned prospective study size of 100 patients evaluated by TAC was selected to balance cost against including sufficient numbers to be able to make a judgement on the card’s clinical utility. As the co-primary endpoint was time to result in a real-world setting that had not been previously evaluated, we did not undertake a formal power calculation.

Metagenomic sequencing
To further validate the results of the prospective TAC assay, metagenomic sequencing was undertaken. Residual BAL samples (average 40 mL) from 98 out of the 100 patients were used for metagenomic sequencing (two could not be sequenced due to presence of potential containment level 3 organisms and lack of a CL3 facility in the sequencing laboratory). BAL was centrifuged at 500 x g for five minutes to separate the host cells (pellet) from the bacterial, viral and fungal pathogens (supernatant). One mL of each sample supernatant was filtered through a 0.45 μm filter and used for viral RNA and DNA extraction using a QIAamp MinElute Virus Spin kit (Qiagen), using an on-column DNase step for viral RNA. Reverse transcription and random amplification of both viral DNA and cDNA was carried out as described previously25. The remaining supernatant was centrifuged at 3220 x g for 30 minutes and the pellet was subjected to host cell depletion using MolYsis Basic5 (Molzym, Bremen, DE) followed by bacterial/fungal DNA extraction using a QIAamp DNA Mini kit (Qiagen, Hilden, DE). Half of the DNA was submitted for HiSeq 4000 shotgun metagenomic sequencing, while the other half was used to amplify the 16S V4 region using barcoded primers20 (The Earth Microbiome Project), amplicons were sequenced by Illumina MiSeq sequencing. All samples were sequenced at the Wellcome Sanger Institute, and raw read data are available at the European Nucleotide Archive (ENA) project PRJEB29011 with study accession numbers ERP111277, ERP111280, ERP112277, and ERP018622. Amplicon data were analysed using Qime2 v2019.10.027. Single-end sequences were denoised using Deblur26, and classified using a feature classifier built from the Greengenes 13.8 99% OTUs taxonomy database. For metagenomic shotgun sequence data, human reads were first removed from the data using Bowtie2 v2.3.528. 5’Human-depleted paired reads were then classified using Kraken2 v2.0.828. For bacterial targets, a curated bacterial database based on the Genome Taxonomy Database31 was used for classification. For viral and fungal pathogens, the standard Kraken2 viral and fungal databases were used. Qime2 and Kraken2 tabular outputs were subsequently processed in R (version 3.5.3) (R core team) to calculate the proportions of reads mapping to individual taxa for each sample.

The outputs for each of the sequencing approaches were compared to paired negative controls and analysed for the presence of fungal, viral and bacterial reads. Fungal and viral organisms were reported if they were the dominant species and/or the read counts were above the determined background levels. Bacterial organisms that were reported if identified by both shotgun and 16S amplicon sequencing, or present as the dominant species in shotgun sequencing above the background levels. Organisms that had low read counts, or were only identified by 16S but were detected by TAC, were reported as low confidence hits.

Results
Technical validation
Following initial validation against stored DNA extracts and synthetic plasmids, all microorganisms from the Quality Control for Molecular Diagnostics 2018 Sepsis EQA Pilot Study were successfully detected (Table 1).

Retrospective cohort validation
The card was tested against the stored samples available from the VAPrapid study17. 128 samples with semi-quantitative culture results were available for analysis. 57 organisms were grown at or above 10⁶ colony forming units (CFU)/ml33, with 55 detected by TAC (Table 2). The TAC detected a further 295 organisms, including 64 viruses and one atypical organism which the recruiting centres did not test for. Excluding tests for organisms not detectable by culture, 3425 tests on TAC were negative. Sensitivity was 97% (95% confidence interval (CI) 88-100%) and specificity 94% (95% CI 93-95%) (Table 3). Organisms detected by both TAC and culture had a median cycles to threshold (Ct) value on the TAC of 29 (interquartile range (IQR) 26–32 range 20–35) whilst culturable organisms detected on TAC but not on culture had a median Ct value of 33 (IQR 30–35 range 20–40) (Figure 2).

Prospective evaluation
Between January 2018 and September 2019, 166 ventilated patients were investigated for pneumonia by bronchoscopy, and 95 were tested by TAC. No proxy decision maker approached refused consent, and 24 patients who regained capacity whilst in hospital were approached and all gave retrospective consent. Five patients were tested twice by TAC, having suffered a subsequent respiratory deterioration, so in total 100 TACs were run. 71 patients formed the comparator group (Figure 3). Although inclusion criteria were pragmatic and only required senior clinician suspicion of pneumonia, 92% of cases met full ECDC criteria for clinical pneumonia (Figure 4). Of the eight cases not meeting full ECDC criteria, one lacked a formal radiological report of infiltrates, one had no clinical signs of pneumonia, five had no signs of systemic inflammation and one patient lacked both radiological and systemic inflammation. Table 4 shows participant characteristics of the study population and comparator group.

Time to result
The median difference in time to result between TAC and conventional culture was 51 hours (IQR 41–69 hours
Table 2. Culture of microorganisms from 128 stored samples from the VAPrapid clinical trial and results from the TAC. (CFU: colony forming units/ml, Ct: cycles to crossing threshold.).

| Organism detected                        | Frequency of growth (≥10^4 CFU/ml) on conventional culture | Frequency by TAC (numbers detected at Ct≤32 shown in brackets) |
|------------------------------------------|--------------------------------------------------------------|---------------------------------------------------------------|
| **Gram negative**                        |                                                              |                                                               |
| Acinetobacter baumannii complex          | 2                                                            | 4 (3)                                                         |
| Enterobacter aerogenes                   | 1                                                            | 0*                                                            |
| Enterobacter cloacae                     | 2                                                            | 7 (5)                                                         |
| Enterococcus faecalis                    | 0                                                            | 2 (1)                                                         |
| Enterococcus faecium                     | 2                                                            | 15 (9)                                                        |
| Escherichia coli                         | 6                                                            | 44 (16)                                                       |
| Enterobacteriaceae (not further specified)| 0                                                            | 7 (3)                                                         |
| Haemophilus influenza                    | 3                                                            | 23 (19)                                                       |
| Haemophilus haemolyticus                 | 1                                                            | 0*                                                            |
| Klebsiella pneumoniae                    | 2                                                            | 13 (6)                                                        |
| Legionella spp. (non-pneumophilia)       | 0                                                            | 1 (1)                                                         |
| Morexella catharralis                    | 1                                                            | 5 (4)                                                         |
| Morganella morganii                      | 0                                                            | 1 (1)                                                         |
| Mycoplasma pneumoniae                    | 0                                                            | 1 (1)                                                         |
| Neisseria meningitidis                   | 0                                                            | 1 (1)                                                         |
| Proteus spp.*                            | 2                                                            | 7 (5)                                                         |
| Pseudomonas aeruginosa                   | 5                                                            | 10 (9)                                                        |
| Serratia marcescens                      | 1                                                            | 5 (3)                                                         |
| **Gram positive**                        |                                                              |                                                               |
| Staphylococcus aureus                    | 21                                                           | 32 (28)                                                       |
| Staphylococcus epidermidis               | 0                                                            | 12 (3)                                                        |
| Other coagulase negative Staphylococcus  | 0                                                            | 9 (1)                                                         |
| Stenotrophomonas maltophilia             | 2                                                            | 11 (5)                                                        |
| Streptococcus pneumoniae                 | 0                                                            | 15 (10)                                                       |
| Streptococcus pyogenes                   | 0                                                            | 1 (1)                                                         |
| Streptococcus spp. (not further specified)| 0                                                            | 37 (25)                                                       |
| **Fungi**                                |                                                              |                                                               |
| Aspergillus fumigatus                    | 0                                                            | 1 (1)                                                         |
| Candida albicans                         | 4                                                            | 17 (7)                                                        |
| Candida spp.                             | 2                                                            | 5 (3)                                                         |
| **Viruses (not tested for by conventional microbiology)** | | |
| Coronavirus OC43                         |                                                              | 1 (1)                                                         |
| Cytomegalovirus                          |                                                              | 6 (1)                                                         |
| Epstein-Barr Virus                       |                                                              | 15 (3)                                                        |
| Herpes simplex virus                     |                                                              | 34 (26)                                                       |
| Influenza A                              |                                                              | 3 (3)                                                         |
| Parainfluenza virus                      |                                                              | 1 (1)                                                         |
| Rhinovirus                               |                                                              | 4 (4)                                                         |

* not on card
* culture reported as Proteus mirabilis, on TAC reported as genus-level Proteus spp.
hours, whilst additional delays with conventional PCR results largely reflect laboratory workflow and batching of samples.

**Comparison of organisms detected by TAC compared to conventional microbiology.** 178 organisms were identified from 100 samples on the TAC (Table 5). Details of individual sample results are available as extended data. Conventional microbiology detected 66 organisms, with 61 detected by TAC. 27 patients had failure of internal control for one or more conventional PCR assays, covering 93 organisms. There were no TAC internal control failures and none of the organisms covered by the failed assays were detected on TAC or sequencing (Table 5). Sensitivity and specificity were 92% (95% CI 83-98%) and 97% (95% CI 97-98%) respectively (Table 6). Including failed and absent reference standards as ‘negative’ had minimal effect on diagnostic performance (Table 7).

**Comparison by sequencing.** 98 samples were available for sequencing. Metagenomic sequencing revealed 107 organisms, 100 of which were also detected by TAC (Table 5 and extended data Table 1). Concerning the 10 organisms detected by conventional microbiology or sequencing but missed by TAC, one organism, that was positive by both culture and sequencing albeit in different patients, was *Citrobacter freundii*, for which we did not have a sequence on the card. A further five pathogens were detected by sequencing (*Staphylococcus aureus*, *Legionella* spp., and *Staphylococcus epidermidis*) or both culture and sequencing (two *E. faecium*). Although these five were detected by TAC, they did not pass the internal quality control standards required for reporting and were considered ‘negative’ results. The remaining three organisms, two rhinovirus by conventional PCR and one *Staphylococcus* spp. by sequencing, were not detected by TAC at all.

One case of *Aspergillus fumigatus* was detected on the TAC, and although no moulds were cultured, the lavage galactomannan antigen test was highly positive (5.92 optical density index [ODI], laboratory reference range <0.5 ODI).

**Quantitation.** Twenty-five organisms were grown on conventional culture at ≥10⁴ CFU/ml, the conventional cut off for quantitative culture of lavage. The median Ct for these organisms on the TAC was 27 (IQR 24-29, range 20–33). In contrast, culturable organisms detected on TAC but not on culture, and therefore likely to be present in lower concentrations and not reported for patients managed without TAC, had a median Ct of 32 (IQR 30-34, range 22–38) (Figure 2).

**Antibiotic prescribing.** Patients in the TAC and comparator cohorts had similar severity of illness, severity of respiratory failure and demographic features (Table 4). Patients managed with the TAC had a significantly different distribution of AFDs to the comparator group in the seven days following bronchoscopy (p=0.02 by Mann-Whitney U-test), with more AFDs in the TAC cohort (Figure 6). This difference did not retain significance over 28 days (Figure 7). Overall 72 (76%) of TAC patients had their antibiotics changed in the seven

---

**Table 3. 2x2 table for TAC vs culture for the retrospective stored sample study.** Results presented for the 29 tests on the TAC covering culturable organisms (ataypical bacteria, viruses and *Pneumocystis jirovecii* excluded).

| Reference standard (microbiological culture) | total |
|---------------------------------------------|-------|
| TAC +ve                                      | 55    |
| TAC -ve                                      | 2     |
| total                                       | 57    |

---

**Figure 2.** Comparison of Cycles to threshold (Ct) for bacteria and fungi detected by culture and TAC (culture +ve) and those which were detected by TAC alone (culture -ve) for both the VAP-RAPID VR (stored) and prospective evaluations. Red line indicates median value **p<0.0001** by Mann-Whitney U test. Organisms which are not detected by standard culture techniques were excluded.
days following bronchoscopy, with a total of 116 changes made (Table 8). In the comparator group 50 (70%) of patients experienced a total of 65 changes. Whilst 63% of decisions in the TAC group led to de-escalation, only 37% of decisions in the comparator group were de-escalation decisions (OR 2.9 (95% CI 1.5-5.5) p=0.008 by Chi-squared). Decisions which were judged to be related to the TAC result were weighted further towards de-escalation (73% of all TAC-related changes, Table 8). 11 (30%) of escalations in the TAC group were judged to have been targeted escalations in response.

Figure 3. Study flow diagram.
to TAC results. In a further six cases negative TAC results prompted investigation for alternative diagnoses.

**Discussion**

We demonstrate that a customised molecular diagnostic, designed to meet the needs of a specific clinical setting, produced accurate results in a clinically important time-frame and was associated with an increase in antibiotic-free days relative to the comparator group in the week following investigation. Diagnostic performance was similar when assessed in stored samples from multiple centres, implying a generalisable result.

Molecular diagnostic platforms for respiratory infection syndromes have, until recently, largely focussed on viral pathogens\(^{16}\). However, the need to optimise antimicrobial therapy whilst limiting the over-use of these drugs has led to repeated calls for bacterial-focussed diagnostics\(^{16,34}\). TACs have been previously reported for use in pneumonia\(^{19,35,36}\). However, apart from our previous report\(^{19}\) that demonstrated limited clinical impact due to restricted organism coverage, none of the other reports have included ventilated patients and were restricted to retrospective analysis of stored samples. Commercial multiple-pathogen arrays that include respiratory bacteria have recently become available, however most reports of their use in ventilated patients remain limited to describing diagnostic performance, and reporting ‘potential’ to change antimicrobial therapy rather than impact on clinical practice\(^{3,37,38}\). Concerns have been raised about the risks of over-treatment from

---

**Clinical and radiological pneumonia case definition — adapted from ECDC criteria\(^{30}\)**

**Radiological**

New or worsening infiltrates on Chest X-ray or CT thorax **AND**

**Clinical**

AND at least one of the following:

- fever > 38°C with no other cause
- leukopenia (< 4 000 WBC/mm\(^3\)) or leucocytosis (≥ 12 000 WBC/mm\(^3\)).
- **AND** at least one of the following
  - new onset of purulent sputum, or change in character of sputum (colour, odour, quantity, consistency)
  - suggestive auscultation (rales or bronchial breath sounds), rhonchi, wheezing
  - worsening gas exchange (e.g. \(O_2\) desaturation or increased oxygen requirements or increased ventilation demand)

---

**Figure 4. Clinical and radiological definition of pneumonia.**
molecular diagnostics16,17,39,40, whilst conversely promising tests with the potential to change therapy have not always proven this in clinical practice15,19. These commercially available assays lack the broad coverage and customisability of the TAC, with consistent concerns raised around limited organism coverage adversely impacting treatment decisions3,17,19,37,38.

There is now widespread acceptance of the presence of a respiratory microbiome41,42 and the lungs of ventilated patients present a challenge to highly sensitive molecular diagnostics16,17. The proximal respiratory tract of ventilated patients becomes rapidly colonised with predominantly Gram negative organisms43,44. This can occur in the absence of infection, and there is a risk that highly sensitive techniques will detect colonising organisms, driving unintended increases in antimicrobial use49. The use of protected lower airway specimens, with growth $\geq 10^4$ CFU/ml for BAL have been used to distinguish infection from colonisation42,28,45. We adapted this approach in this study, using the quasi-quantitative Ct value provided by RT-PCR and testing protected bronchoalveolar samples. Using the comparison of the Ct values of organisms detected by culture and those detected by TAC without culture, we suggest that a Ct threshold of 32 be used to suggest infecting rather than colonising organism (Figure 2 and Figure 8).

One of the problems that has beset bacterial diagnostics studies has been the absence of a ‘gold standard’ against which the candidate can be assessed6,34,46, as conventional culture is imperfect. For this study we supplemented comparison against conventional microbiology (culture and viral PCR) with metagenomic sequencing. 10 organisms identified by conventional microbiology or sequencing were not detected by the TAC. Overall, the TAC detected more organisms than either culture or sequencing, reflecting the higher sensitivity of qPCR. However, without a perfect validation method we cannot be certain these were not ‘false positives’ and have counted them as such for the calculation of specificity. The sequencing and culture results give clinicians considerable confidence in the results provided.

The selection of organisms targeted on the card was crucial, and informed by our previous experience where omission of key organisms significantly limited the impact of a similar card19. Given the case mix of our unit, with a high proportion of immunosuppressed patients, we opted to include a number of low pathogenicity organisms, (i.e. coagulase-negative Staphylococci (CNS), Enterococci and Candida albicans), as well as Herpesviridae, which were routinely tested for prior to this study. The detection of these organisms can be challenging to interpret47, given that many critically ill patients have a degree of immunoparesis, even if not classically immunosuppressed48, and so their significance remains uncertain. As our laboratory routinely reported these organisms on conventional microbiology the clinical team were already confronted with this issue.

It is increasingly apparent that the microbiome of the lungs of ventilated patients undergoes a shift, with increasing dominance of enteric organisms which may enter the lungs via gut

| Parameter | TAC patients (95 patients) | Comparator group (71 patients) |
|-----------|---------------------------|-------------------------------|
| Median age (range) | 60 (21–86) | 62 (18–83) |
| n (%) female | 41 (43 %) | 27 (38 %) |
| Median (IQR) functional comorbidity index | 1 (2) | 1 (2) |
| n (%) with community-acquired pneumonia | 34 (36%) | 20 (28%) |
| n (%) hospital-acquired pneumonia of HAP n (%) ventilator-associated | 61 (64%) | 51 (72%) |
| Median (IQR) APACHE II score on admission | 16 (10) | 16 (9) |
| % receiving antibiotics at time of lavage | 82% | 96% |
| Median (IQR) FiO₂ prior to bronchoscopy | 0.5 (0.25) | 0.5 (0.30) |
| Median (IQR) white cell count ($\times 10^9$/L) | 10.5 (12.4) | 10.7 (9.5) |
| Median (IQR) neutrophil count ($\times 10^9$/L) | 8.6 (11.5) | 8.8 (8.63) |
| Median (IQR) C-reactive protein concentration (mg/L) | 198 (153) | 146 (154) |
| 28-day mortality n (%) | 30 (32%) | 21 (30%) |

Table 4. Baseline characteristics of study population. APACHE II, acute physiology and chronic health evaluation II, FiO₂, fraction of inspired oxygen. (IQR: interquartile range).
translocation and microaspiration\textsuperscript{49,50}. Determining whether enteric organisms, even those such as E coli which are conventionally considered pathogenic in the lung, are the cause or the consequence of pulmonary inflammation remains a challenge. However this is a challenge which besets both conventional and molecular diagnostics, and one which is likely to take further developments in host-response diagnostics to resolve\textsuperscript{10,13,15,41,44}

The inclusion of CNS aids with the interpretation of the detection of the mecA gene, which is commonly carried by these organisms, thus helping identify MRSA. The lack of CNS sequences on commercial cards has been noted to impair interpretation of mecA detection on other molecular diagnostic platforms\textsuperscript{37,51}. The ready customisability of the TAC would allow units to remove such organisms, as well as add other organisms that emerge as a threat as we have done subsequently during the COVID-19 pandemic\textsuperscript{52}. Although we undertook the steps noted in the methods section to validate the TAC prior to use, the range of organisms encountered in the retrospective and prospective cohorts’ clinical samples did not cover the full range of organisms on the TAC. Some organisms not seen in this report had been detected in previous studies using the same assays in an earlier iteration of the card\textsuperscript{18,19}. We must therefore be somewhat cautious about the interpretation of the assays without clinical sample validation, and continue to monitor card performance as experience with this card develops in our centre.

The use of a contemporaneous comparator cohort allowed for comparisons of antibiotic prescribing within the context of the implementation of the TAC and any heightened awareness of antimicrobial stewardship it may have engendered. Despite this, the comparator cohort saw a greater proportion of escalation decisions in the week following lavage, and had

**Figure 5.** Time to result for TAC, conventional culture and conventional polymerase chain reactions. Bold line indicates median value. Median difference in test results vs TAC was 51hrs (IQR 41-69) for culture, 21 (IQR 16-40) for Epstein-Barr virus/ cytomegalovirus (EBV/CMV), 16 (IQR 5-21) for respiratory virus multiplex, 19 (IQR 15-25) for Herpes Simplex Virus (HSV) and 42 (IQR 22-70) for Pneumocystis jirovecii (PC). P<0.001 by Kruskal-Wallis, **** p<0.001 by Dunn’s post-hoc test.

**Table 5.** Summary of organisms detected by conventional microbiological testing (left hand column), by TAC (middle column), and by microbial sequencing (right hand column).

| Organism detected         | Frequency (by conventional microbiology) | Frequency (by TAC) | Frequency (by sequencing) |
|---------------------------|------------------------------------------|--------------------|---------------------------|
| Bacteria                  |                                          |                    |                           |
| Citrobacter freundii      | 1*                                       | 0                  | 1*                        |
| Enterobacter cloacae      | 2                                        | 8                  | 3                         |
| Enterococcus faecalis     | 0                                        | 3                  | 0                         |
| Enterococcus faecium      | 3                                        | 7                  | 7                         |
| Escherichia coli          | 6                                        | 14                 | 6                         |
| Klebsiella pneumoniae     | 3                                        | 5                  | 3                         |
| Enterobacteriaceae        | 0                                        | 1                  | 2                         |
| (not further specified)   |                                          |                    |                           |
| Haemophilus influenzae    | 0                                        | 3                  | 2                         |
| Legionella pneumophila    | 1**                                      | 1                  | 1                         |
| Organism detected                          | Frequency (by conventional microbiology) | Frequency (by TAC) | Frequency (by sequencing) |
|-------------------------------------------|------------------------------------------|-------------------|---------------------------|
| Legionella spp. (non-pneumophilia)        | 0                                        | 2                 | 2                         |
| Morexella catharralis                     | 0                                        | 1                 | 0                         |
| Mycoplasma pneumoniae                     | 0                                        | 1                 | 1                         |
| Proteus spp.                              | 0                                        | 2                 | 0                         |
| Pseudomonas aeruginosa                    | 2                                        | 5                 | 4                         |
| Serratia marcescens                       | 1                                        | 3                 | 0                         |
| Staphylococcus aureus                     | 2                                        | 8                 | 8                         |
| Staphylococcus epidermidis                | 0                                        | 9                 | 2                         |
| Other coagulase negative Staphylococcus   | 0                                        | 1                 | 2                         |
| Other Staphylococcus spp. (not further specified) | 0                                        | 0                 | 1                         |
| Stenotrophomonas maltophilia              | 2                                        | 4                 | 2                         |
| Streptococcus pneumoniae                  | 1                                        | 9                 | 6                         |
| Streptococcus pyogenes                    | 0                                        | 1                 | 0                         |
| Streptococcus spp. (not further specified) | 0                                        | 23                | 10                        |
| Mixed upper respiratory tract flora        | 1                                        | N/A               | N/A                       |

**Fungi**

| Aspergillus spp.                           | 0***                                      | 1                 | 0                         |
| Candida albicans                           | 1                                        | 12                | 10                        |
| Candida spp.                               | 0                                        | 1                 | 1                         |
| Pneumocystis jirovecii                     | 4                                        | 4                 | 3                         |

**Viruses**

| Coronavirus#                               | 0                                        | 3                 | 1                         |
| Cytomegalovirus                            | 5                                        | 7                 | 4                         |
| Epstein-Barr Virus                         | 1                                        | 6                 | 1                         |
| Herpes simplex virus                       | 7                                        | 11                | 7                         |
| Human metapneumovirus                      | 1                                        | 1                 | 1                         |
| Influenza A                                | 7                                        | 7                 | 5                         |
| Influenza B                                | 3                                        | 3                 | 2                         |
| Parainfluenza virus                        | 4                                        | 4                 | 4                         |
| Rhinovirus                                 | 8                                        | 8                 | 7                         |

* One hit not found in same patient; not on card. **Legionella urinary antigen test positive. *** Positive bronchoalveolar lavage galactomannan enzyme immunoassay (>0.5 units) with CT consistent with fungal pneumonia and known risk factors but fungal cultures were not positive. # refers to human coronavirade OC43, 229E and NL63, no tests were undertaken for
Table 6. 2x2 table for TAC vs conventional microbiology for prospective study patients. Results presented for the 43 organisms routinely tested for in the laboratory, excluding 93 tests for patients where conventional PCR failed internal controls.

| Reference standard (conventional culture/PCR) | totals |
|---------------------------------------------|--------|
| TAC +ve                                      | -ve    |
| +ve                                         | 61     |
| -ve                                         | 5      |
| totals                                      | 4141   |

Table 7. 2x2 table for TAC vs conventional microbiology for prospective study patients. Results presented for all 52 organisms tested on the card, with missing standard tests due to conventional PCR assay failure and non-testing treated as 'negative tests'. Sensitivity and specificity were 92% (95% CI 83-98%) and 98% (95% CI 97-98%).

| Reference standard (conventional culture/PCR) | totals |
|---------------------------------------------|--------|
| TAC +ve                                      | -ve    |
| +ve                                         | 61     |
| -ve                                         | 5      |
| totals                                      | 5134   |

Implementation of TaqMan array

Our experience leads us to suggest the following approach to using the TAC. Where a pathogenic organism(s) is detected at Ct value of ≤32, antimicrobials can be adjusted to target the organism(s) detected, in light of known local resistance patterns and the patient’s history carriage of antimicrobial-resistant organisms. Pathogenic organisms detected at a Ct of >32 are likely to be colonisers or contaminants, although detection of respiratory viruses or obligate pathogens such as *Legionella* spp or *Mycoplasma pneumoniae* at higher Ct values remains significant. The detection of low pathogenicity organisms needs to be interpreted in light of the patient’s known or suspected immune status. Among the immunocompromised, high levels of such organisms, especially if it is the sole pathogen detected, may prompt treatment. In patients in whom no relevant pathogens are detected (i.e. all organisms are at low levels, low fewer antibiotic-free days. The 28 day mortality was similar between the two groups, and both had similar duration of ventilation and ICU length of stay (Table 4), which suggests that the change in antibiotic therapy was not associated with harm. The lack of difference in AFDs at day 28 is unsurprising, as suspected pneumonia is only one of multiple drivers of antibiotic use. Although the comparator and TAC groups had similar characteristics, our observational design means that we cannot be certain that unmeasured confounders did not contribute to the effects seen. Replication in additional settings with distinct approaches to stewardship is required before we can be certain of its external generalisability, whilst evaluation in a randomised, controlled trial would help reduce any bias that may have arisen from our observational study design.

Figure 6. Distribution of days alive and free of antibiotics in the seven days following bronchoscopy and lavage in the TAC and comparator cohorts. Following first lavage only for patients who had more than one bronchoalveolar lavage during ICU admission. Numbers in each category and percentage shown below graph, p value by Mann-Whitney U test.
pathogenicity organisms are detected in immunocompetent hosts, or no organisms are detected at all) consideration should be given to alternative sites of infection, alternative diagnoses and where clinical suspicion of infection is low, stopping antibiotics (Figure 8). We used the TAC in the context of an existing daily microbiology-ICU multi-disciplinary team meeting, and as noted above generalisability of our findings to other contexts will require replication in those settings. We

![Figure 7](image-url) Distribution of days alive and free of antibiotics in the twenty eight days following bronchoscopy and lavage in the TAC and comparator cohorts. Following first lavage only for patients who had more than one bronchoalveolar lavage during ICU admission. P-value by Mann-Whitney U test.

| Antibiotic change       | Details of change                                                                 | TAC cohort | Comparator cohort |
|-------------------------|-----------------------------------------------------------------------------------|------------|-------------------|
|                         |                                                                                   | TAC-related | TAC-unrelated     |
| **De-escalation**       | Stopping macrolides                                                              | 14         | 3                 | 6                 |
|                         | Stopping carbapenem or anti-pseudomonal penicillin                              | 10         | 14                | 10                |
|                         | Narrowing from carbapenem/antipseudomonal penicillin to narrower spectrum penicillin | 7         | 0                 | 1                 |
|                         | Stopping cotrimoxazole                                                           | 6*         | 1                 | 0                 |
|                         | Stopping antivirals                                                              | 3          | 0                 | 0                 |
|                         | Stopping aminoglycosides                                                         | 2          | 3                 | 0                 |
|                         | Stopping other agents                                                            | 6          | 4                 | 7                 |
| **Escalation**          | Start antivirals                                                                  | 7          | 0                 | 1                 |
|                         | Start or broaden antifungals cover                                               | 3          | 7**               | 6                 |
|                         | Broadened Gram negative cover (add anti-pseudomonal penicillin, aminoglycoside or carbapenem) | 3          | 16                | 28                |
|                         | Add glycopeptide                                                                  | 4          | 1                 | 5                 |
|                         | Add cover for atypical organism                                                   | 1          | 1                 | 1                 |
Figure 8. Schematic representation of the proposed clinical decision tree arising from the results of the TaqMan array.

note that further clinical sample validation is required for rare organisms not encountered in our retrospective and prospective cohorts. Confirmation of safety of TAC-driven changes in antimicrobials will be best established in prospective randomised trials.

Conclusions
This study established a molecular diagnostic test to meet the needs of a particular intensive care unit, although generalisability was demonstrated through testing samples from multiple other units. The strength of the TAC is that it allows customisation and rapid modification to address emerging threats and ensure broad coverage. Implementation in the context of an antimicrobial stewardship program led to significant impact on antimicrobial prescribing. We believe this approach represents a promising new approach to the management of severe pneumonia but this requires testing in the context of well-designed randomised clinical trials.

Data availability
Underlying data
European Nucleotide Archive (ENA): Bronchialveolar_lavage_metagenomics (Project PRJEB29011). Accession number ERP111277; https://identifiers.org/ena.embl:ERP111277

ENA: BAL_metagenomics__viral_enrichment (Project: PRJEB29014). Accession number: ERP111280; https://identifiers.org/ena.embl:ERP111280

ENA: Bronchialveolar_lavage_microbiome (Project: PRJEB29919). Accession number: ERP112277; https://identifiers.org/ena.embl:ERP112277

ENA: ICU_metagenomics_Using_16S_rRNA_analysis_for_assessing_the_respiratory_bacterial_infection_threat_to_immunocompromised_patients_within_Intensive_Care_Units (Project: PRJEB16762). Accession number: ERP018622; https://identifiers.org/ena.embl:ERP018622

Patient data is not publicly available for confidentiality reasons in line with the approved study protocol, but anonymised data can be obtained through contact with the corresponding author, subject to appropriate data sharing agreements being in place. Data sharing agreements will be arranged by Cambridge University Hospitals NHS Foundation Trust, as the study sponsor.

Extended data
Zenodo: Rapid Pathogen Identification in Ventilated Patients with Pneumonia. https://doi.org/10.5281/zenodo.5081880
This project contains the following data:
- TAC protocol.docx (study protocol)

Zenodo: Use of antibiotics in ICU patients undergoing lavage-based diagnosis of pneumonia -protocol for retrospective study
https://doi.org/10.5281/zenodo.5519073

This project contains the following data
- anonymised data BAL protocol 1point 1 5 2 20.pdf

Zenodo: TaqMan array sequence set for 52-target respiratory pathogen array. https://doi.org/10.5281/zenodo.5519133

This project contains the following data
- VAP 96 TAC card sequence file.pdf

Zenodo: Extended data table 1: Taqman array card results showing all individual target hits with Ct values and whether validated by conventional microbiology and/or microbial sequencing. https://doi.org/10.5281/zenodo.5519136

This project contains the following data
- Extended data table 1.pdf

Reporting guidelines
Zenodo: STARD checklist for ‘Development and implementation of a customised rapid syndromic diagnostic test for severe pneumonia’. https://doi.org/10.5281/zenodo.508193

Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).

Authors contributions (CReDIT)
VN -Conceptualisation, resources, investigation, writing-review and editing, project administration, funding acquisition, supervision.
JBS -resources, investigation, data curation, formal analysis, writing-original draft.
MM-resources, investigation, writing-review and editing.
TH-resources, investigation, writing-review and editing
EH-investigation, writing-review and editing.
SF-investigation, writing-review and editing.
JD-investigation, writing-review and editing.
SP-investigation, writing-review and editing.
EHH-investigation, writing-review and editing.
PP-investigation, data curation, writing-review and editing.
JB-investigation, data curation, writing-review and editing.
LT-investigation, data curation, writing-review and editing.
JS- resources, investigation, writing-review and editing
AR- resources, investigation, writing-review and editing
MR-data curation, writing-review and editing.
DS-data curation, writing-review and editing.
MET-conceptualisation, investigation, data curation writing-review and editing
RMcM- resources, investigation, writing-review and editing
DE-investigation, writing-review and editing.
VW-formal analysis, investigation, data curation writing-review and editing.
VAPrapid investigators-resources and investigation.
MDC-Conceptualisation, resources, investigation, writing-review and editing, project administration, funding acquisition, supervision.
NB-Conceptualisation, resources, investigation, writing-review and editing, project administration, supervision.
AJS- resources, investigation, writing-review and editing
JH-Conceptualisation, resources, investigation, writing-review and editing.
GD-Conceptualisation, resources, investigation, writing-review and editing, project administration, funding acquisition, supervision.
ACM-Conceptualisation, methodology, resources, investigation, writing-original draft, project administration, formal analysis, funding acquisition, supervision.

Acknowledgements
The VAPrapid investigators are Prof DF McAuley, Prof TS Walsh, Dr N Anderson, Dr S Singh, Prof P Dark, Dr A Roy, Prof GD Perkins, Ms L Emerson, Prof B Blackwood, Dr SE Wright, D K Kefala, Prof CM O’Kane, Dr SV Baudouin, Dr RL. Patterson, Dr A Agus, Dr J Bamard-Smith, Dr NM Robbin, Prof ID Welters, Dr C Bassford, Dr B Yates, Dr C Spencer, Dr SK Laha, Dr J Hulme, Prof S Bonner, Dr V Linnett, Dr J Sonsken, Dr Van Den Broeck, Dr G Boschman, Mr DWJ Kennan, Dr AJ Allan, Mr G Phair, Ms J Parker and Dr SA Bowett.

The authors thank the consultant intensivists of the John V Farman Intensive Care Unit, Drs P Bradley, P Featherstone, S Ford, M Georgieva, A Johnston, R Mahroof, J Martin, J Preller, K Patel, C Summers, M Trivedi, J Varley, Pharmacist L Radford, the nursing and physiotherapy teams who managed the patients, and the patients and their families who consented to the study. We also thank Torsten Seemann for access to his Kraken database.

A previous version of this manuscript was deposited as a preprint on MedRxiv medRxiv (https://doi.org/10.1101/2020.06.02.20118489).
References

1. Cilloniz C, Ewig S, Polverino E, et al.: Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax. 2011; 66(4): 340–346. PubMed Abstract | Publisher Full Text
2. Vincent JL, Sakr Y, Singer M, et al.: Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017. JAMA. 2020; 323(15): 1478–1487. PubMed Abstract | Publisher Full Text | Free Full Text
3. Gadsby NJ, McHugh MP, Forbes C, et al.: Comparison of Unyvero P55 Pneumonia Card, in-house PCR and culture for the identification of respiratory pathogens and antibiotic resistance in bronchoalveolar lavage fluids in critical care setting. Eur J Clin Microbiol Infect Dis. 2019; 38(6): 1171–1178. PubMed Abstract | Publisher Full Text
4. Arulkumaran N, Routledge M, Schiebusch S, et al.: Antimicrobial-associated harm in critical care: a narrative review. Intensive Care Med. 2020; 46(2): 225–235. PubMed Abstract | Publisher Full Text | Free Full Text
5. Iregui M, Ward S, Sherman G, et al.: Clinical Importance of Delays in the Initiation of Appropriate Antibiotic Treatment for Ventilator-Associated Pneumonia. Chest. 2002; 122(1): 262–269. PubMed Abstract | Publisher Full Text | Free Full Text
6. Morris AC: Management of pneumonia in intensive care. J Emerg Crit Care Med. 2016; 2: 101–107. Publisher Full Text
7. Rangel-Frausto MS, Pittet D, Costigan M, et al.: The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA. 1995; 273(2): 117–5. PubMed Abstract | Publisher Full Text
8. Lichtenstein D, Goldstein I, Mourgeon E, et al.: Causes of fever and pulmonary densities in patients with clinical manifestations of ventilator-associated pneumonia. Chest. 1994; 106(1): 221–235. PubMed Abstract | Publisher Full Text
9. Conway Morris A, Kefala K, Wilkinson TS, et al.: Diagnostic importance of pulmonary interleukin-1beta and interleukin-8 in ventilator-associated pneumonia. Thorax. 2010; 65(3): 201–207. PubMed Abstract | Publisher Full Text | Free Full Text
10. Povoa P, Coelho L, Almeida E, et al.: C-reactive protein as a marker of ventilator-associated pneumonia resolution: a pilot study. Eur Respir J. 2005; 25(5): 804–812. PubMed Abstract | Publisher Full Text
11. Pfister R, Kochanek M, Leygeber T, et al.: Procalcitinin for diagnosis of bacterial pneumonia in critically ill patients during 2009 H1N1 influenza pandemic: a prospective cohort study, systematic review and individual patient data meta-analysis. Crit Care. 2014; 18(2): R44. PubMed Abstract | Publisher Full Text | Free Full Text
12. Hellyer TP, Morris AC, McAuley DF, et al.: Diagnostic accuracy of pulmonary host inflammatory mediators in the exclusion of ventilator-acquired pneumonia. Thorax. 2015; 70(1): 41–47. PubMed Abstract | Publisher Full Text
13. Huang DT, Yeal OM, Fillim MR, et al.: Procalcitonin-Guided Use of Antibiotics for Lower Respiratory Tract Infection. N Engl J Med. 2018; 379(5): 236–249. PubMed Abstract | Publisher Full Text | Free Full Text
14. Hellyer TP, McCaulay OF, Walsh TS, et al.: Biomarker-guided antibiotic stewardship in suspected ventilator-associated pneumonia (VAPapid2): a randomised controlled trial and process evaluation. Lancet Respir Med. 2020; 8(2): 182–191. PubMed Abstract | Publisher Full Text | Free Full Text
15. Hanso KE, Azar MM, Banerjee R, et al.: Molecular Testing for Acute Respiratory Tract Infections: Clinical and Diagnostic Recommendations From the IDSA’s Diagnostics Committee. Clin Infect Dis. 2020; 71(10): 2744–2751. PubMed Abstract | Publisher Full Text | Free Full Text
16. Pandolfos AM, Horne R, Jani V, et al.: Intensivists’ beliefs about rapid multiplex molecular diagnostic testing and its potential role in improving prescribing decisions and antimicrobial stewardship: a qualitative study. Antimicrob Resist Infect Control. 2021; 10(1): 95. PubMed Abstract | Publisher Full Text | Free Full Text
17. Steensels D, Reynolds M, Descheemaker R, et al.: Clinical evaluation of a multi-parameter customized respiratory TaqMan®(®) array card compared to conventional methods in immunocompromised patients. J Clin Virol. 2015; 72: 36–41. PubMed Abstract | Publisher Full Text | Free Full Text
18. Jones N, Conway Morris A, Curran MD, et al.: Evaluating the use of a 22-Pathogen TaqMan array card for rapid diagnosis of respiratory pathogens in Intensive Care. J Med Microbiol. 2020; 69(7): 971–978. PubMed Abstract | Publisher Full Text
19. Vilas N, Conway Morris A: Rapid Pathogen Identification in Ventilated Patients with Pneumonia (1.5). Zenodo. 2021. http://www.doii.org/10.5281/zenodo.5081880
20. Gadsby NJ, Russell CD, McHugh MP, et al.: Comprehensive Molecular Testing for Respiratory Pathogens in Community-Acquired Pneumonia. Clin Infect Dis. 2016; 62(7): 817–823. PubMed Abstract | Publisher Full Text | Free Full Text
21. Heaney J, Rolfe K, Gleedall NS, et al.: Low-Density TaqMan® Array Cards for the Detection of Pathogens. In: Current and Emerging Technologies for the Diagnosis of Microbial Infections. Methods in Microbiology. Elsevier; 2015; 42: 199–218. Publisher Full Text
22. Curran MD: TaqMan array sequence set for S2-target respiratory pathogen array. Zenodo. 2021. http://www.doii.org/10.5281/zenodo.559133
23. Caporaso JG, Lauber CL, Walters WA, et al.: Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample. Proc Natl Acad Sci USA. 2011; 108 Suppl 1(Suppl 1): 4516–4522. PubMed Abstract | Publisher Full Text | Free Full Text
24. Bolyen E, Rideout JR, Dillon MR, et al.: Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat Biotechnol. 2019; 37(8): 852–857. PubMed Abstract | Publisher Full Text | Free Full Text
25. Parks DH, Navas-Molina JA, et al.: Deblurring Rapidly Resolves Single-Nucleotide Community Sequence Patterns. Gilbert JA, ed. mSystems; 2017; 2(2): e00191-16. PubMed Abstract | Publisher Full Text | Free Full Text
26. Langmead B, Salzberg SL: Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012; 9(4): 357–359. PubMed Abstract | Publisher Full Text | Free Full Text
27. Wood DE, Lu, J; Langmead B: Improved metagenomic analysis with Kraken 2. Genome Biol. 2019; 20(1): 257. PubMed Abstract | Publisher Full Text | Free Full Text
28. Plachouras D, Lepape A, Sueters C: ECDC definitions and methods for the surveillance of healthcare-associated infections in intensive care units. Intensive Care Med. 2018; 44(12): 2216–2218. PubMed Abstract | Publisher Full Text | Free Full Text
29. Navadiparkar V, Bartholdson Scott J, Maes M, et al.: Extended data table 1: Tagman array card results showing all individual target hits with Ct values and whether validated by conventional microbiology and/or microbial sequencing. Zenodo. 2021. http://www.doii.org/10.5281/zenodo.559133
30. The Lancet Respiratory Medicine: Pneumonia research: time to fill in the gaps. Lancet Respir Med. 2019; 7(12): 993. PubMed Abstract | Publisher Full Text | Free Full Text
31. Wolff BJ, Bramley AM, Thurman KA, et al.: Improved Detection of Respiratory Pathogens by Use of High-Quality Sputum with TaqMan Array Card Technology. Onderdonk AB, ed. Clin Microbiol. 2016; 55(1): 110–121. PubMed Abstract | Publisher Full Text | Free Full Text
32. Hercik C, Cosmas L, Mogeni OD, et al.: A diagnostic and epidemiologic investigation of acute febrile illness (AFC) in Kilombero, Tanzania. Schildgen O, ed. Plos One; 2017; 12(1): e0189720. PubMed Abstract | Publisher Full Text | Free Full Text
33. Peiffer-Smadja N, Bouadma L, Mathy V, et al.: Performance and impact of a multiplex PCR in ICU patients with ventilator-associated pneumonia or ventilated hospital-acquired pneumonia. Crit Care. 2020; 24(1): 366. PubMed Abstract | Publisher Full Text | Free Full Text
34. Monard C, Pehlivan J, Auger G, et al.: Multicenter evaluation of a syndromic rapid multiplex PCR test for early adaptation of antimicrobial therapy in adult patients with pneumonia. Crit Care. 2020; 24(1): 434. PubMed Abstract | Publisher Full Text | Free Full Text
35. Houben RMG, Lalli M, Kranner K, et al.: What if They Don’t Have Tuberculosis? The Consequences and Trade-offs Involved in False-positive Diagnoses of Tuberculosis. Clin Infect Dis. 2019; 68(1): 150–156. PubMed Abstract | Publisher Full Text | Free Full Text
36. Weinrib DA, Capraro GA: The Uncertain Clinical Benefit of the T2Bacteria
41. Nolan TJ, Gadsby NJ, Hellyer TP, et al.: Low-pathogenicity Mycoplasma spp. alter human monocyte and macrophage function and are highly prevalent among patients with ventilator-acquired pneumonia. Thorax. 2016; 71(7): 594-600. PubMed Abstract | Publisher Full Text

42. Zakharkina T, Martin-Loeches I, Matamoros S, et al.: The dynamics of the pulmonary microbiome during mechanical ventilation in the intensive care unit and the association with occurrence of pneumonia. Thorax. 2017; 72(9): 803-810. PubMed Abstract | Publisher Full Text

43. Ewig S, Torres A, El-Ebiary M, et al.: Bacterial colonization patterns in mechanically ventilated patients with traumatic and medical head injury. Incidence, risk factors, and association with ventilator-associated pneumonia. Am J Respir Crit Care Med. 1999; 159(1): 188-198. PubMed Abstract | Publisher Full Text

44. Roquilly A, Torres A, Villadangos JA, et al.: Pathophysiological role of respiratory dysbiosis in hospital-acquired pneumonia. Lancet Respir Med. 2018; 6(5): 452-461. PubMed Abstract | Publisher Full Text

45. Morris AC, Kefala K, Simpson AJ, et al.: Evaluation of the effect of diagnostic methodology on the reported incidence of ventilator-associated pneumonia. Thorax. 2009; 64(4): 516-522. PubMed Abstract | Publisher Full Text

46. Bhat N, O'Brien KL, Karron RA, et al.: Use and Evaluation of Molecular Diagnostics for Pneumonia Etiology Studies. Clin Infect Dis. 2012; 54 Suppl 2(Suppl 2): S153-S158. PubMed Abstract | Publisher Full Text | Free Full Text

47. Hagel S, Scherag A, Schuierer L, et al.: Effect of antiviral therapy on the outcomes of mechanically ventilated patients with herpes simplex virus detected in the respiratory tract: a systematic review and meta-analysis. Crit Care. 2020; 24(1): 584-10. PubMed Abstract | Publisher Full Text

48. Morris AC, Datta D, Shankar-Hari M, et al.: Cell-surface signatures of immune dysfunction risk-stratify critically ill patients: INFECT study. Intensive Care Med. 2018; 44(5): 627-635. PubMed Abstract | Publisher Full Text | Free Full Text

49. Dickson RP, Schultz MJ, Poll T van der, et al.: Lung Microbiota Predict Clinical Outcomes in Critically Ill Patients. Am J Resp Crit Care Med. 2020; 201(3): 505-563. PubMed Abstract | Publisher Full Text | Free Full Text

50. Dickson RP, Singer BH, Newstead MW, et al.: Enrichment of the lung microbiome with gut bacteria in sepsis and the acute respiratory distress syndrome. Nature Microbiol. 2016; 1(10): 16113. PubMed Abstract | Publisher Full Text | Free Full Text

51. Weiser DM, Wallace MA, Burnham CA, et al.: Evaluation of the BioFire FilmArray Pneumonia Panel for Detection of Viral and Bacterial Pathogens in Lower Respiratory Tract Specimens in the Setting of a Tertiary Care Academic Medical Center. J Clin Microbiol. 2020; 58:7: e00343-20. PubMed Abstract | Publisher Full Text | Free Full Text

52. Maes M, Higginson E, Pereira-Dias J, et al.: Ventilator-associated pneumonia in critically ill patients with COVID-19. Crit Care. 2021; 25(1): 25. PubMed Abstract | Publisher Full Text | Free Full Text

53. Conway Morris A: Use of antibiotics in ICU patients undergoing lavage-based diagnosis of pneumonia-protocol for retrospective study (1.1). Zenodo. 2021. http://www.doi.org/10.5281/zenodo.5519073

54. Conway Morris A: STARD checklist for Development and implementation of a customised rapid syndromic diagnostic test for severe pneumonia. Zenodo. 2021. http://www.doi.org/10.5281/zenodo.5081937
Open Peer Review

Current Peer Review Status:  

Version 3

Reviewer Report 28 October 2022

https://doi.org/10.21956/wellcomeopenres.20471.r52795

© 2022 Haak B. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

✅ Bastiaan Haak  
Center for Experimental and Molecular Medicine, Amsterdam Infection & Immunity Institute, Amsterdam UMC, location AMC, University of Amsterdam, Amsterdam, The Netherlands

The authors have addressed my comments appropriately.

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Infectious disease, (lung) microbiome

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 2

Reviewer Report 29 June 2022

https://doi.org/10.21956/wellcomeopenres.19815.r51054

© 2022 Haak B. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

❓ Bastiaan Haak  
Center for Experimental and Molecular Medicine, Amsterdam Infection & Immunity Institute, Amsterdam UMC, location AMC, University of Amsterdam, Amsterdam, The Netherlands

The authors present an interesting manuscript in which they describe the potential of an agnostic molecular diagnostic approach (TAC) for direct detection of emerging pathogens from clinical...
specimens in patients with pneumonia. They show that their approach yields highly sensitive results in significantly shorter time as compared to time required for culture-dependent assays. In addition, they demonstrate that the use of TAC led to a significant reduction in antibiotic free days, which could be of importance in improving antibiotic stewardship practices. Overall, the manuscript is well written and the methodological steps are sound. This manuscript has been reviewed extensively prior to my review, and I do not have much to add.

However, I agree with reviewer 1 that certain pitfalls will have to be addressed before such methods can be used as part of widespread clinical practice. A specific point of concern is the use of TAC on broncho-alveolar lavage samples leading to the detection of high amounts of bacterial communities originating from the gastrointestinal tract (i.e. *Escherichia coli* and *Enterococcus spp.*). It is unclear to what extent these bacteria contribute to clinical disease, as recent studies have shown that it is likely that these microbial communities translocate from the gut into the lower airways following the development of a respiratory infection. Therefore, identification of these bacteria complicates rational antibiotic selection, as it is unclear if these bacteria are the cause or the effect of the disease. This point has been raised by reviewer 1 in the context of the high detection rates of *Candida* in the TAC cohort. However, I would request the authors to write an additional paragraph in which these specific limitations are addressed.

References
1. Dickson R, Singer B, Newstead M, Falkowski N, et al.: Enrichment of the lung microbiome with gut bacteria in sepsis and the acute respiratory distress syndrome. *Nature Microbiology*. 2016; 1 (10). [Publisher Full Text](#)
2. Dickson R, Schultz M, van der Poll T, Schouten L, et al.: Lung Microbiota Predict Clinical Outcomes in Critically Ill Patients. *American Journal of Respiratory and Critical Care Medicine*. 2020; 201 (5): 555-563 [Publisher Full Text](#)

Is the rationale for developing the new method (or application) clearly explained?  
Yes

Is the description of the method technically sound?  
Yes

Are sufficient details provided to allow replication of the method development and its use by others?  
Yes

If any results are presented, are all the source data underlying the results available to ensure full reproducibility?  
Yes

Are the conclusions about the method and its performance adequately supported by the findings presented in the article?  
Yes

**Competing Interests:** No competing interests were disclosed.
Reviewer Expertise: Infectious disease, (lung) microbiome

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 10 Oct 2022

Andrew Conway Morris,

We thank the reviewer for their comments. The reviewer is correct that distinguishing infecting organisms from organisms that colonise the respiratory tract is a challenge. It is one which besets both conventional, culture-based microbial diagnostics as well as molecular diagnostics. Furthermore it is unclear to what extent changes in the pulmonary microbiome contribute to the syndrome of pneumonia as it is recognised by clinicians. This is not something that can be resolved by this study, but we have added the following section to the discussion to acknowledge the issues raised.

“It is increasingly apparent that the microbiome of the lungs of ventilated patients undergoes a shift, with increasing dominance of enteric organisms which may enter the lungs via gut translocation and microaspiration46,47. Determining whether enteric organisms, even those such as E coli which are conventionally considered pathogenic in the lung, are the cause or the consequence of pulmonary inflammation remains a challenge. However this is a challenge which besets both conventional and molecular diagnostics, and one which is likely to take further developments in host-response diagnostics to resolve 10,13,15,38,41.”

Competing Interests: MDC is the inventor on a patent held by the Secretary of State for Health (UK Government) EP2788503, which covers some of the genetic sequences used in this study. VN is a founder, Director and shareholder in Cambridge Infection Diagnostics Ltd (CID Ltd) which is a commercial company aimed at developing molecular diagnostics in infection and antimicrobial and AMR stewardship. NMB, GD and ACM are members of the Scientific Advisory Board of Cambridge Infection Diagnostics Ltd (CID Ltd). All other authors declare no conflict of interest.
Manchester, UK

I have no further comments. The authors have addressed my previous comments/questions appropriately.

Is the rationale for developing the new method (or application) clearly explained?
Yes

Is the description of the method technically sound?
Yes

Are sufficient details provided to allow replication of the method development and its use by others?
Yes

If any results are presented, are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions about the method and its performance adequately supported by the findings presented in the article?
Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Infection diagnostics, antibiotic pharmacology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
pathogens in critically ill adults. The manuscript is well written and easy to read.

Commercial multiplex PCR diagnostic assays would be expected to demonstrate the sensitivity and specificity of each of the individual assays. Whilst this is onerous given that some of the pathogens are uncommon, some of the PCR targets are not present at all in the validation cohort. The authors make no comment of safety related to changing antibiotic prescribing. Given that some of the targets are unvalidated and the PCR result may have resulted in antibiotics being withheld or stopped early it would be helpful to understand the outcome of patients.

It is unclear to me how the TaqMan assay results in a reduction in antibiotics given the huge number of pathogens identified in patients. The authors state that the results were released into clinical practice without specific advice but presumably some advice was given as to which pathogens not to treat? Additionally the diagnostic accuracy analysis is a little misleading given how much better the new test performs compared to the gold standard. Is a conventional diagnostic accuracy analysis the best analysis to perform?

A lot of Candida species was identified in the respiratory tract. Candida is generally considered a coloniser in the lung and not a cause of pneumonia. Did the authors treat each of the cases of candida? More detail of the management of candida in the lung is required – did these patients all receive antifungal therapy? If candida was regarded as a colonising organism it should be considered a negative result in the diagnostic accuracy analysis.

Overall a really interesting manuscript. I think a number of issues need to be addressed before this assay can be rolled out into clinical practice: validation of the rare pathogens, patient safety, out performance of the gold standard. It would strengthen the manuscript if the authors added a section to the discussion to outline next steps. This would make it clearer that the assay is not ready for mass adoption (which is suggested).

Is the rationale for developing the new method (or application) clearly explained?
Yes

Is the description of the method technically sound?
Yes

Are sufficient details provided to allow replication of the method development and its use by others?
Yes

If any results are presented, are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions about the method and its performance adequately supported by the findings presented in the article?
No

**Competing Interests:** No competing interests were disclosed.
Reviewer Expertise: Infection diagnostics, antibiotic pharmacology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 05 May 2022
Andrew Conway Morris,

We thank Dr Felton for his review and comments. To address each in turn

R1: Commercial multiplex PCR diagnostic assays would be expected to demonstrate the sensitivity and specificity of each of the individual assays. Whilst this is onerous given that some of the pathogens are uncommon, some of the PCR targets are not present at all in the validation cohort.

A1: We acknowledge that whilst the samples tested in both the retrospective cohort validation and prospective evaluation contained a wide range of organisms they did not include all organisms for which we have sequences on the card. Previous studies (Steensals D et al and Jones N et al, references 18 and 19 in the manuscript) used many of the same assays used in this TAC, and identified some organisms not seen in our cohort. As noted in the methods, ‘technical validation section’, we did test the sequences on the cards against synthetic control plasmids to ensure their technical function, and also tested against extracts from known positive cultures in the lab. For atypical organisms where we did not have positive cultures in the lab (C burnetti, C psittaci, C pneumonia and M pneumoniae) commercially available controls were purchased from Vircell, Granada, Spain. The only organism which was validated entirely by synthetic control plasmid was Elizabethkingia meningoseptica, which was a prevalent organism in our hospital 5 years ago but has not been detected on culture recently. We agree that detection in clinical samples with confirmed culture of these organisms would be the gold standard. With the card being used in Cambridge University Hospitals for adult pneumonia, and an ongoing study in paediatric pneumonia we have continued to accumulate data and review card performance regularly. Through this, some of the targets that were not validated in clinical samples this study have subsequently been validated. We have adjusted the methods to include further information regarding technical validation against clinical culture and commercial controls, and altered the discussion section to highlight this potential issue.

The specific changes are methods “……covering all targets except C burnetti, C psittaci, C pneumonia, M pneumoniae and Elizabethkingia meningoseptica. For C burnetti, C psittaci, C pneumonia and M pneumoniae control DNA extracts were purchased (Vircell, Granada, Spain, Catalogue numbers MBC018, MBC013, MBC011 and MBC035 respectively). “

Discussion “Although we undertook the steps noted in the methods section to validate the TAC prior to use, the range of organisms encountered in the retrospective and prospective cohorts’ clinical samples did not cover the full range of organisms on the TAC. Some organisms not seen in this report had been detected in previous studies using the same
assays in an earlier iteration of the card\textsuperscript{18,19}. We must therefore be somewhat cautious about the interpretation of the assays without clinical sample validation, and continue to monitor card performance as experience with this card develops in our centre.”

**R2:** The authors make no comment of safety related to changing antibiotic prescribing. Given that some of the targets are unvalidated and the PCR result may have resulted in antibiotics being withheld or stopped early it would be helpful to understand the outcome of patients.

**A2:** We agree that safety is an important outcome, and note in the introduction that potential for harm may cut both ways (reference 4 summarising the evidence of antimicrobial harm, whilst reference 5 speaks to the risks of delayed and inappropriate therapy). Although we reported mortality being similar between the comparator and prospective TAC evaluation groups (table 4) in the context of demographically similar groups, we have now included data showing similar duration of ICU stay and duration of ventilation. We have added a note of these values in the discussion, and we noted previously that a randomised study would be the best way to address the potential of residual confounding.

**R3:** It is unclear to me how the TaqMan assay results in a reduction in antibiotics given the huge number of pathogens identified in patients. The authors state that the results were released into clinical practice without specific advice but presumably some advice was given as to which pathogens not to treat? Additionally the diagnostic accuracy analysis is a little misleading given how much better the new test performs compared to the gold standard. Is a conventional diagnostic accuracy analysis the best analysis to perform?

**A3:** We examined the antibiotic therapy following lavage, and whilst we agree that the TAC did detect more organisms we also found that when changes occurred this tended to be towards de-escalation, although there were examples of targeted escalations as well. Although we have looked at decisions around the initiation or cessation of individual antibiotics and their relationship to the TAC, we acknowledge in the paper that this judgement is inherently subjective. This is why our primary analysis of antibiotic use is overall antibiotic-free days between the groups and change in antibiotics, which are taken from the drug prescriptions and thus do not require subjective judgement. This is likely to under-estimate the impact of the TAC as some antibiotics may be prescribed for reasons other than suspected pneumonia.

In terms of microbiology advice, being in the study did not mandate a specific course of action. Whilst results were released to the clinical team, our unit has a daily microbiology-ICU multi-disciplinary round where all microbiology results (including those from the TAC) are considered and decisions made around antimicrobial prescription. This is noted in the methods, ‘return of results to the clinical team’ section. In the discussion we noted “Replication in additional settings with distinct approaches to stewardship is required before we can be certain of its external generalisability”. We have further emphasised this in the discussion section ‘implementation of the TaqMan array’ with an additional sentence
“We used the TAC in the context of an existing daily microbiology-ICU multi-disciplinary team meeting, and as noted above generalisability of our findings to other contexts will require replication in those settings.”

We agree that conventional measures of diagnostic accuracy are difficult in evaluation of tests with greater sensitivity than the existing clinical standard. This does run the risk of understating the apparent specificity of the test, as we note in the discussion “Overall, the TAC detected more organisms than either culture or sequencing, reflecting the higher sensitivity of qPCR. However, without a perfect validation method we cannot be certain these were not ‘false positives’ and have counted them as such for the calculation of specificity” however we felt that understating the apparent specificity and acknowledging this risk was the best approach. Equally we acknowledge that culture may miss organisms that are not culturable, which is why we undertook the sequencing. The lack of a consensus standard on the interpretation of sequencing for clinical samples meant that we didn’t include these data as part of the primary outcome measure of sensitivity (which was vs conventional microbiology), but reported them separately. However we think that the data from both conventional microbiology and sequencing are supportive of the diagnostic performance of the TAC. We feel that presenting the summary diagnostic test performance as % sensitivity and % specificity is the most easily interpretable presentation, and is consistent with our pre-defined study protocol outcomes.

R4: A lot of Candida species was identified in the respiratory tract. Candida is generally considered a coloniser in the lung and not a cause of pneumonia. Did the authors treat each of the cases of candida? More detail of the management of candida in the lung is required – did these patients all receive antifungal therapy? If candida was regarded as a colonising organism it should be considered a negative result in the diagnostic accuracy analysis.

A4: We agree that candida in the lung are not normally considered a cause of pneumonia and in only two cases were anti-fungals started by the treating clinicians on the basis of detection of candida (table 8), one of these patients was immunocompromised and the other had an oesophageal perforation and both were considered to be at risk of systemic candidiasis. The third initiation of antifungals noted in table 3 was in response to the detection of aspergillus on the TAC. Our diagnostic accuracy referred to the detection of organisms rather than the detection of pneumonia, so we compared all organisms detected on TAC to those detected by conventional microbiology without inferring a diagnosis of pneumonia. Pneumonia remains a difficult diagnosis to make in ventilated patients and we think that detection or non-detection of organisms is a more objective measure. We discuss our reasons for including ‘low pathogenicity organisms’ on the TAC in the discussion section.

R5: Overall a really interesting manuscript. I think a number of issues need to be addressed before this assay can be rolled out into clinical practice: validation of the rare pathogens, patient safety, out performance of the gold standard. It would strengthen the manuscript if the authors added a section to the discussion to outline next steps. This would make it
clearer that the assay is not ready for mass adoption (which is suggested).

**A5:** We thank Dr Felton for these comments. As per A1 above, we agree that assays for rare organisms that have not been previously validated need to be validated in clinical samples alongside our culture and synthetic plasmid validation. We also agree that testing at other sites, ideally in the context of a randomised controlled trial, would help address the questions of generalisability and safety of this approach. We have added further sentences to the discussion section, implementation of the TaqMan array and conclusions to emphasise these points. These additional sentences are “We note that further clinical sample validation is required for rare organisms not encountered in our retrospective and prospective cohorts. Confirmation of safety of TAC-driven changes in antimicrobials will be best established in prospective randomised trials” and “We believe this approach represents a promising new approach to the management of severe pneumonia but this requires testing in the context of well-designed randomised clinical trials.”

**Competing Interests:** As per original submission